Scopolamine as an Antidepressant: A Systematic Review
The cholinergic-adrenergic hypothesis of mania and depression states that depression is characterized by an increase in central cholinergic activity relative to noradrenergic tone. Scopolamine is a centrally acting competitive inhibitor of the muscarinic cholinergic receptor site. This review seeks...
Gespeichert in:
| Veröffentlicht in: | Clinical neuropharmacology 2013, Vol.36 (1), p.24-26 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 26 |
|---|---|
| container_issue | 1 |
| container_start_page | 24 |
| container_title | Clinical neuropharmacology |
| container_volume | 36 |
| creator | JAFFE, Robert J NOVAKOVIC, Vladan PESELOW, Eric D |
| description | The cholinergic-adrenergic hypothesis of mania and depression states that depression is characterized by an increase in central cholinergic activity relative to noradrenergic tone. Scopolamine is a centrally acting competitive inhibitor of the muscarinic cholinergic receptor site. This review seeks to find all available data investigating scopolamine as an antidepressant.
A systematic review of all the published and unpublished or ongoing literature was conducted via Ovid MEDLINE. Keywords used for the search were "scopolamine hydrobromide" in association with one of the following: "depression," "antidepressive agents," "depressive disorder," "depression, chemical," and "affect." PubMed was also searched using "scopolamine" (all fields) and "antidepressant" (all fields) or "depression" (all fields).
A small study with elderly patients failed to show a statistically significant improvement in depression when measured at 120 minutes after infusion. A second small, well-controlled study using intramuscular scopolamine showed a small but statistically significant improvement in depression on the morning after the second dose was received. Two double-blind randomized placebo-controlled crossover trials with intravenous scopolamine 4.0 μg/kg infusions showed a significant improvement in depressive symptoms seen as soon as 3 days after the first treatment. Further data analyses showed a greater antidepressant effect in women, significant improvements in bipolar depression, and 85% success rates predicting who will respond to treatment.
Scopolamine is an effective and rapid antidepressant in both unipolar and bipolar depression, working as quickly as 3 days after initial infusion. Independent replication would greatly enhance the literature. |
| doi_str_mv | 10.1097/WNF.0b013e318278b703 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1315624882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273698317</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-db65de6265409135d1dc773cc1a6ccc3c9bd7cdf201ac8e8dbb3eb1173d3bbc13</originalsourceid><addsrcrecordid>eNqFkE1LAzEURYMotlb_gchsBDejeXkzScZdKVaFomAV3Q3JSwoj81EnU6X_3pFWBTeu7ubce-Ewdgz8HHimLp7vpufcckCPoIXSVnHcYUNIUcUgxcsuG3KUIk6lTAbsIIRXzrnOkmyfDQQiJlzBkKVzapZNaaqi9pEJkamjcd0Vzi9bH4Kpu8toHM3XofOV6QqKHvx74T8O2d7ClMEfbXPEnqZXj5ObeHZ_fTsZz2JCyLrYWZk6L4VME54Bpg4cKYVEYCQRIWXWKXILwcGQ9tpZi94CKHRoLQGO2Nlmd9k2bysfurwqAvmyNLVvViEHhFSKRGvxPyoUykxjPz5iyQaltgmh9Yt82RaVadc58PzLbd67zf-67Wsn24eVrbz7KX3L7IHTLWACmXLRmpqK8MspnvUuNH4C12WB3A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273698317</pqid></control><display><type>article</type><title>Scopolamine as an Antidepressant: A Systematic Review</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>JAFFE, Robert J ; NOVAKOVIC, Vladan ; PESELOW, Eric D</creator><creatorcontrib>JAFFE, Robert J ; NOVAKOVIC, Vladan ; PESELOW, Eric D</creatorcontrib><description>The cholinergic-adrenergic hypothesis of mania and depression states that depression is characterized by an increase in central cholinergic activity relative to noradrenergic tone. Scopolamine is a centrally acting competitive inhibitor of the muscarinic cholinergic receptor site. This review seeks to find all available data investigating scopolamine as an antidepressant.
A systematic review of all the published and unpublished or ongoing literature was conducted via Ovid MEDLINE. Keywords used for the search were "scopolamine hydrobromide" in association with one of the following: "depression," "antidepressive agents," "depressive disorder," "depression, chemical," and "affect." PubMed was also searched using "scopolamine" (all fields) and "antidepressant" (all fields) or "depression" (all fields).
A small study with elderly patients failed to show a statistically significant improvement in depression when measured at 120 minutes after infusion. A second small, well-controlled study using intramuscular scopolamine showed a small but statistically significant improvement in depression on the morning after the second dose was received. Two double-blind randomized placebo-controlled crossover trials with intravenous scopolamine 4.0 μg/kg infusions showed a significant improvement in depressive symptoms seen as soon as 3 days after the first treatment. Further data analyses showed a greater antidepressant effect in women, significant improvements in bipolar depression, and 85% success rates predicting who will respond to treatment.
Scopolamine is an effective and rapid antidepressant in both unipolar and bipolar depression, working as quickly as 3 days after initial infusion. Independent replication would greatly enhance the literature.</description><identifier>ISSN: 0362-5664</identifier><identifier>EISSN: 1537-162X</identifier><identifier>DOI: 10.1097/WNF.0b013e318278b703</identifier><identifier>PMID: 23334071</identifier><identifier>CODEN: CLNEDB</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Acetylcholine receptors ; Acetylcholine receptors (muscarinic) ; Adult and adolescent clinical studies ; Affective disorders ; Antidepressants ; Antidepressive Agents - therapeutic use ; Biological and medical sciences ; Clinical trials ; Data processing ; Depression ; Depressive Disorder - drug therapy ; Depressive Disorder - epidemiology ; Depressive Disorder - psychology ; Geriatrics ; Humans ; Intravenous administration ; Medical sciences ; Mood disorders ; Muscarinic Antagonists - therapeutic use ; Neuropharmacology ; Norepinephrine ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Randomized Controlled Trials as Topic - methods ; Replication ; Reviews ; Scopolamine ; Scopolamine Hydrobromide - therapeutic use ; Statistical analysis</subject><ispartof>Clinical neuropharmacology, 2013, Vol.36 (1), p.24-26</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c319t-db65de6265409135d1dc773cc1a6ccc3c9bd7cdf201ac8e8dbb3eb1173d3bbc13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4010,27904,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27096268$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23334071$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JAFFE, Robert J</creatorcontrib><creatorcontrib>NOVAKOVIC, Vladan</creatorcontrib><creatorcontrib>PESELOW, Eric D</creatorcontrib><title>Scopolamine as an Antidepressant: A Systematic Review</title><title>Clinical neuropharmacology</title><addtitle>Clin Neuropharmacol</addtitle><description>The cholinergic-adrenergic hypothesis of mania and depression states that depression is characterized by an increase in central cholinergic activity relative to noradrenergic tone. Scopolamine is a centrally acting competitive inhibitor of the muscarinic cholinergic receptor site. This review seeks to find all available data investigating scopolamine as an antidepressant.
A systematic review of all the published and unpublished or ongoing literature was conducted via Ovid MEDLINE. Keywords used for the search were "scopolamine hydrobromide" in association with one of the following: "depression," "antidepressive agents," "depressive disorder," "depression, chemical," and "affect." PubMed was also searched using "scopolamine" (all fields) and "antidepressant" (all fields) or "depression" (all fields).
A small study with elderly patients failed to show a statistically significant improvement in depression when measured at 120 minutes after infusion. A second small, well-controlled study using intramuscular scopolamine showed a small but statistically significant improvement in depression on the morning after the second dose was received. Two double-blind randomized placebo-controlled crossover trials with intravenous scopolamine 4.0 μg/kg infusions showed a significant improvement in depressive symptoms seen as soon as 3 days after the first treatment. Further data analyses showed a greater antidepressant effect in women, significant improvements in bipolar depression, and 85% success rates predicting who will respond to treatment.
Scopolamine is an effective and rapid antidepressant in both unipolar and bipolar depression, working as quickly as 3 days after initial infusion. Independent replication would greatly enhance the literature.</description><subject>Acetylcholine receptors</subject><subject>Acetylcholine receptors (muscarinic)</subject><subject>Adult and adolescent clinical studies</subject><subject>Affective disorders</subject><subject>Antidepressants</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Data processing</subject><subject>Depression</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - epidemiology</subject><subject>Depressive Disorder - psychology</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Intravenous administration</subject><subject>Medical sciences</subject><subject>Mood disorders</subject><subject>Muscarinic Antagonists - therapeutic use</subject><subject>Neuropharmacology</subject><subject>Norepinephrine</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Randomized Controlled Trials as Topic - methods</subject><subject>Replication</subject><subject>Reviews</subject><subject>Scopolamine</subject><subject>Scopolamine Hydrobromide - therapeutic use</subject><subject>Statistical analysis</subject><issn>0362-5664</issn><issn>1537-162X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEURYMotlb_gchsBDejeXkzScZdKVaFomAV3Q3JSwoj81EnU6X_3pFWBTeu7ubce-Ewdgz8HHimLp7vpufcckCPoIXSVnHcYUNIUcUgxcsuG3KUIk6lTAbsIIRXzrnOkmyfDQQiJlzBkKVzapZNaaqi9pEJkamjcd0Vzi9bH4Kpu8toHM3XofOV6QqKHvx74T8O2d7ClMEfbXPEnqZXj5ObeHZ_fTsZz2JCyLrYWZk6L4VME54Bpg4cKYVEYCQRIWXWKXILwcGQ9tpZi94CKHRoLQGO2Nlmd9k2bysfurwqAvmyNLVvViEHhFSKRGvxPyoUykxjPz5iyQaltgmh9Yt82RaVadc58PzLbd67zf-67Wsn24eVrbz7KX3L7IHTLWACmXLRmpqK8MspnvUuNH4C12WB3A</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>JAFFE, Robert J</creator><creator>NOVAKOVIC, Vladan</creator><creator>PESELOW, Eric D</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>2013</creationdate><title>Scopolamine as an Antidepressant: A Systematic Review</title><author>JAFFE, Robert J ; NOVAKOVIC, Vladan ; PESELOW, Eric D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-db65de6265409135d1dc773cc1a6ccc3c9bd7cdf201ac8e8dbb3eb1173d3bbc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acetylcholine receptors</topic><topic>Acetylcholine receptors (muscarinic)</topic><topic>Adult and adolescent clinical studies</topic><topic>Affective disorders</topic><topic>Antidepressants</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Data processing</topic><topic>Depression</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - epidemiology</topic><topic>Depressive Disorder - psychology</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Intravenous administration</topic><topic>Medical sciences</topic><topic>Mood disorders</topic><topic>Muscarinic Antagonists - therapeutic use</topic><topic>Neuropharmacology</topic><topic>Norepinephrine</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Randomized Controlled Trials as Topic - methods</topic><topic>Replication</topic><topic>Reviews</topic><topic>Scopolamine</topic><topic>Scopolamine Hydrobromide - therapeutic use</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JAFFE, Robert J</creatorcontrib><creatorcontrib>NOVAKOVIC, Vladan</creatorcontrib><creatorcontrib>PESELOW, Eric D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Clinical neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JAFFE, Robert J</au><au>NOVAKOVIC, Vladan</au><au>PESELOW, Eric D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Scopolamine as an Antidepressant: A Systematic Review</atitle><jtitle>Clinical neuropharmacology</jtitle><addtitle>Clin Neuropharmacol</addtitle><date>2013</date><risdate>2013</risdate><volume>36</volume><issue>1</issue><spage>24</spage><epage>26</epage><pages>24-26</pages><issn>0362-5664</issn><eissn>1537-162X</eissn><coden>CLNEDB</coden><abstract>The cholinergic-adrenergic hypothesis of mania and depression states that depression is characterized by an increase in central cholinergic activity relative to noradrenergic tone. Scopolamine is a centrally acting competitive inhibitor of the muscarinic cholinergic receptor site. This review seeks to find all available data investigating scopolamine as an antidepressant.
A systematic review of all the published and unpublished or ongoing literature was conducted via Ovid MEDLINE. Keywords used for the search were "scopolamine hydrobromide" in association with one of the following: "depression," "antidepressive agents," "depressive disorder," "depression, chemical," and "affect." PubMed was also searched using "scopolamine" (all fields) and "antidepressant" (all fields) or "depression" (all fields).
A small study with elderly patients failed to show a statistically significant improvement in depression when measured at 120 minutes after infusion. A second small, well-controlled study using intramuscular scopolamine showed a small but statistically significant improvement in depression on the morning after the second dose was received. Two double-blind randomized placebo-controlled crossover trials with intravenous scopolamine 4.0 μg/kg infusions showed a significant improvement in depressive symptoms seen as soon as 3 days after the first treatment. Further data analyses showed a greater antidepressant effect in women, significant improvements in bipolar depression, and 85% success rates predicting who will respond to treatment.
Scopolamine is an effective and rapid antidepressant in both unipolar and bipolar depression, working as quickly as 3 days after initial infusion. Independent replication would greatly enhance the literature.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>23334071</pmid><doi>10.1097/WNF.0b013e318278b703</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0362-5664 |
| ispartof | Clinical neuropharmacology, 2013, Vol.36 (1), p.24-26 |
| issn | 0362-5664 1537-162X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1315624882 |
| source | MEDLINE; Journals@Ovid Ovid Autoload |
| subjects | Acetylcholine receptors Acetylcholine receptors (muscarinic) Adult and adolescent clinical studies Affective disorders Antidepressants Antidepressive Agents - therapeutic use Biological and medical sciences Clinical trials Data processing Depression Depressive Disorder - drug therapy Depressive Disorder - epidemiology Depressive Disorder - psychology Geriatrics Humans Intravenous administration Medical sciences Mood disorders Muscarinic Antagonists - therapeutic use Neuropharmacology Norepinephrine Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Randomized Controlled Trials as Topic - methods Replication Reviews Scopolamine Scopolamine Hydrobromide - therapeutic use Statistical analysis |
| title | Scopolamine as an Antidepressant: A Systematic Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A10%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Scopolamine%20as%20an%20Antidepressant:%20A%20Systematic%20Review&rft.jtitle=Clinical%20neuropharmacology&rft.au=JAFFE,%20Robert%20J&rft.date=2013&rft.volume=36&rft.issue=1&rft.spage=24&rft.epage=26&rft.pages=24-26&rft.issn=0362-5664&rft.eissn=1537-162X&rft.coden=CLNEDB&rft_id=info:doi/10.1097/WNF.0b013e318278b703&rft_dat=%3Cproquest_cross%3E1273698317%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273698317&rft_id=info:pmid/23334071&rfr_iscdi=true |